{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:20:06Z","timestamp":1774952406128,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.eururo.2020.08.033","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T17:45:14Z","timestamp":1599759914000},"page":"655-656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"79","author":[{"given":"Alexander","family":"Andreev-Drakhlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6328-9599","authenticated-orcid":false,"given":"Arlene","family":"Siefker-Radtke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2020.08.033_bib0005","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","article-title":"Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy","volume":"79","author":"Leow","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.08.033_bib0010","first-page":"3158","article-title":"Prospective controlled observation of effect of adjuvant chemotherapy on survival and prognosis of high-risk upper tract urothelial carcinoma patients underwent radical nephroureterectomy","volume":"99","author":"Luo","year":"2019","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.eururo.2020.08.033_bib0015","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT tril): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2020.08.033_bib0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2017.01.032","article-title":"Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers","volume":"76","author":"Petrelli","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2020.08.033_bib0025","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.08.033_bib0030","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.08.033_bib0035","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JU.0000000000000644","article-title":"Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma","volume":"203","author":"Margulis","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.08.033_bib0040","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.08.033_bib0045","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2020.08.033_bib0050","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2008.06.013","article-title":"FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours","volume":"55","author":"van Oers","year":"2009","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820306837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283820306837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:09:18Z","timestamp":1759583358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283820306837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S0302283820306837"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2020.08.033","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.07.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}